Buy Rating Affirmed for 908 Devices on Strong Market Position and Growth Prospects
TD Cowen Maintains 908 Devices(MASS.US) With Buy Rating
908 Devices Analyst Ratings
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), Aurinia Pharmaceuticals (AUPH) and 908 Devices (MASS)
Stifel Nicolaus Remains a Buy on 908 Devices (MASS)
Stephens & Co. Reiterates Overweight on 908 Devices, Maintains $14 Price Target
908 Devices Analyst Ratings
908 Devices (MASS) Receives a Buy From SVB Securities
908 Devices Analyst Ratings
Stephens & Co. Initiates Coverage On 908 Devices With Overweight Rating, Announces Price Target of $14
Analysts Offer Insights on Healthcare Companies: Moderna (MRNA), 908 Devices (MASS) and Privia Health Group (PRVA)
SVB Securities Sticks to Its Buy Rating for 908 Devices (MASS)
SVB Securities Adjusts 908 Devices' Price Target to $20 From $30, Keeps Outperform Rating
908 Devices Analyst Ratings
SVB Leerink Maintains Outperform on 908 Devices, Lowers Price Target to $20
SVB Securities Keeps Their Buy Rating on 908 Devices (MASS)
908 Devices Analyst Ratings
SVB Leerink Maintains Outperform on 908 Devices, Lowers Price Target to $25
SVB Securities Keeps Their Buy Rating on 908 Devices (MASS)
No Data
No Data